Acne Therapies for the Primary Care Physician: What’s New and What’s Practical
DOI:
https://doi.org/10.58931/cpct.2025.3244Abstract
Acne vulgaris is the most common dermatologic condition worldwide, affecting people across a broad range of ages and skin phototypes. There are a variety of pathophysiological processes involved in the formation of acne lesions, with available anti-acne therapies targeting such pathways. Herein, we provide a review of important acne treatment classes and present novel topical, oral and energy-based interventions.
References
Wu L, Zhu SC, He Y, Zhu YX, Ou-Yang XL, Zhang D, et al. Current perspectives for metabolomics and lipidomics in dyslipidemia of acne vulgaris: a mini review. Front Med (Lausanne). 2024;11:1538373. doi:10.3389/fmed.2024.1538373 DOI: https://doi.org/10.3389/fmed.2024.1538373
Del Rosso J, Farris PK, Harper J, Baldwin H, Hazan A, Raymond I. New insights into systemic drivers of inflammation and their contributions to the pathophysiology of acne. J Drugs Dermatol. 2024;23(2):90-96. doi:10.36849/jdd.8137 DOI: https://doi.org/10.36849/JDD.8137
Bettoli V, Guerra-Tapia A, Herane MI, Piquero-Martín J. Challenges and solutions in oral isotretinoin in acne: reflections on 35 years of experience. Clin Cosmet Investig Dermatol. 2019;12:943-951. doi:10.2147/ccid.S234231 DOI: https://doi.org/10.2147/CCID.S234231
Eichenfield L, Hebert A, Desai SR, Levy ML, Mancini AJ, Rice ZP, et al. The new face of preadolescent and adolescent acne: beyond the guidelines. J Fam Pract. 2022;71(6 Suppl):S63-s70. doi:10.12788/jfp.0430 DOI: https://doi.org/10.12788/jfp.0430
Fabbrocini G, Ferrillo M, Donnarumma M, Papale A, Pinto D, Rinaldi F. A randomized, double-blind, placebo-controlled, multicentric study to evaluate the efficacy and the tolerability of a class ii medical device in the treatment of mild and moderate acne. Dermatol Ther (Heidelb). 2022;12(8):1835-1845. doi:10.1007/s13555-022-00767-1 DOI: https://doi.org/10.1007/s13555-022-00767-1
Del Rosso JQ. The role of skin care as an integral component in the management of acne vulgaris: part 1: the importance of cleanser and moisturizer ingredients, design, and product selection. J Clin Aesthet Dermatol. 2013;6(12):19-27.
Baldwin H, Bui H, Callender V, Frey C, Hebert A, Ted E, et al. The use of acneceuticals to improve acne care: introduction of a new term and review of the literature. J Drugs Dermatol. 2025;24(3):281-288. doi:10.36849/jdd.8817 DOI: https://doi.org/10.36849/JDD.8817
Li M, Lynde C, Sibley C, Bernstein SC, Mathieu S, Guenther L, et al. A multicentre evaluation of a ceramide-containing hydrating cream-to-foam cleanser and facial moisturizing lotion for improving topical treatment tolerability in facial acne. J Cutan Med Surg. 2025;29(1_suppl):3s-13s. doi:10.1177/12034754241304729 DOI: https://doi.org/10.1177/12034754241304729
Schachner L, Alexis A, Andriessen A, Baldwin H, Cork M, Kirsner R, et al. Supplement individual article: the importance of a healthy skin barrier from the cradle to the grave using ceramide-containing cleansers and moisturizers: a review and consensus. J Drugs Dermatol. 2023;22(2):SF344607s344603-SF344607s344614.
Alexis AF, Woolery-Lloyd H, Williams K, Andriessen A, Callender VD, Kang S, et al. Racial/ethnic variations in acne: implications for treatment and skin care recommendations for acne patients with skin of color. J Drugs Dermatol. 2021;20(7):716-725. doi:10.36849/jdd.6169 DOI: https://doi.org/10.36849/JDD.6312
Lain E, Andriessen AE. Choosing the right partner: complementing prescription acne medication with over-the-counter cleansers and moisturizers. J Drugs Dermatol. 2020;19(11):1069-1075. doi:10.36849/jdd.2020.5536 DOI: https://doi.org/10.36849/JDD.2020.5536
Isoda K, Seki T, Inoue Y, Umeda K, Nishizaka T, Tanabe H, et al. Efficacy of the combined use of a facial cleanser and moisturizers for the care of mild acne patients with sensitive skin. J Dermatol. 2015;42(2):181-188. doi:10.1111/1346-8138.12720 DOI: https://doi.org/10.1111/1346-8138.12720
Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby KM, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1001-1006.e1030. doi:10.1016/j.jaad.2023.12.017 DOI: https://doi.org/10.1016/j.jaad.2023.12.017
Gürel RC, Yıldırım M, Erturan İ, Korkmaz S, Kumbul Doğuç D. Measurement of acne severity, dietary habits, and blood zonulin levels in acne patients. J Cosmet Dermatol. 2025;24(3):e70083. doi:10.1111/jocd.70083 DOI: https://doi.org/10.1111/jocd.70083
Ryguła I, Pikiewicz W, Kaminiów K. Impact of diet and nutrition in patients with acne vulgaris. Nutrients. 2024;16(10). doi:10.3390/nu16101476 DOI: https://doi.org/10.3390/nu16101476
Min M, Tarmaster A, Bodemer A, Sivamani RK. The influence of a plant-based diet on skin health: inflammatory skin diseases, skin healing, and plant-based sources of micro- and macro-nutrients. Life (Basel). 2024;14(11). doi:10.3390/life14111439 DOI: https://doi.org/10.3390/life14111439
Borrego-Ruiz A, Borrego JJ. Nutritional and microbial strategies for treating acne, alopecia, and atopic dermatitis. Nutrients. 2024;16(20). doi:10.3390/nu16203559 DOI: https://doi.org/10.3390/nu16203559
Guertler A, Neu K, Lill D, Clanner-Engelshofen B, French LE, Reinholz M. Exploring the potential of omega-3 fatty acids in acne patients: A prospective intervention study. J Cosmet Dermatol. 2024;23(10):3295-3304. doi:10.1111/jocd.16434 DOI: https://doi.org/10.1111/jocd.16434
Mirnezami M, Rahimi H. Is oral omega-3 effective in reducing mucocutaneous side effects of isotretinoin in patients with acne vulgaris? Dermatol Res Pract. 2018;2018:6974045. doi:10.1155/2018/6974045 DOI: https://doi.org/10.1155/2018/6974045
Zainab Z, Malik NA, Obaid S, Malik S, Aftab K, Mumtaz M, et al. Effectiveness of oral omega 3 in reducing mucocutaneous side effects of oral isotretinoin in patients with acne vulgaris. J Ayub Med Coll Abbottabad. 2021;33(1):60-63.
Daszkiewicz M, Różańska D, Regulska-Ilow B. The relationship between chocolate consumption and the severity of acne lesions-a crossover study. Foods. 2024;13(13). doi:10.3390/foods13131993 DOI: https://doi.org/10.3390/foods13131993
Raza Q, Hina RE, Nawaz S, Safdar M, Imran K, Ashraf U, et al. Effect of a low-glycemic-load diet and dietary counseling on acne vulgaris severity among female patients aged 15 to 35 years. Cureus. 2024;16(11):e72886. doi:10.7759/cureus.72886 DOI: https://doi.org/10.7759/cureus.72886
Dodds M, Bodemer A, Shields BE. What’s diet got to do with it? Basic and clinical science behind diet and acne. Cutis. 2022;110(1):13-16. doi:10.12788/cutis.0565 DOI: https://doi.org/10.12788/cutis.0565
Meixiong J, Ricco C, Vasavda C, Ho BK. Diet and acne: a systematic review. JAAD Int. 2022;7:95-112. doi:10.1016/j.jdin.2022.02.012 DOI: https://doi.org/10.1016/j.jdin.2022.02.012
Conforti C, Agozzino M, Emendato G, Fai A, Fichera F, Marangi GF, et al. Acne and diet: a review. Int J Dermatol. 2022;61(8):930-934. doi:10.1111/ijd.15862 DOI: https://doi.org/10.1111/ijd.15862
Zha M, Usatine R. Common skin conditions in children and adolescents: acne. FP Essent. 2024;541:7-13.
Matin T, Patel P, Goodman MB. Benzoyl Peroxide. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.; 2025.
Kircik LH. The role of benzoyl peroxide in the new treatment paradigm for acne. J Drugs Dermatol. 2013;12(6):s73-76.
Lynde C, Abdulla S, Andriessen A, Hanna S, Jafarian F, Li M, et al. INDIVIDUAL ARTICLE: real-world cases of clascoterone topical treatment for acne and related disorders. J Drugs Dermatol. 2025;24(1):73361s73363-73361s73314. doi:10.36849/jdd.73361 DOI: https://doi.org/10.36849/JDD.73361
Tay E, Loo WJ. Real-world experience of clascoterone cream 1% in acne management: case series and Canadian experience. Clin Cosmet Investig Dermatol. 2025;18:161-167. doi:10.2147/ccid.S498879 DOI: https://doi.org/10.2147/CCID.S498879
Basendwh MA, Alharbi AA, Bukhamsin SA, Abdulwahab RA, Alaboud SA. The efficacy of topical clascoterone versus systematic spironolactone for treatment of acne vulgaris: a systematic review and network meta-analysis. PLoS One. 2024;19(5):e0298155. doi:10.1371/journal.pone.0298155 DOI: https://doi.org/10.1371/journal.pone.0298155
Gupta AK, Mann A, Vincent K, Abramovits W. CABTREO(TM) (Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide) topical gel. Skinmed. 2024;22(5):375-378.
Stein Gold L, Baldwin H, Kircik LH, Weiss JS, Pariser DM, Callender V, et al. Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: a randomized phase ii study of the first triple-combination drug. Am J Clin Dermatol. 2022;23(1):93-104. doi:10.1007/s40257-021-00650-3 DOI: https://doi.org/10.1007/s40257-021-00650-3
Zip C. Tazarotene lotion 0.045% for the treatment of acne. Skin Therapy Lett. 2022;27(4):1-3.
Miranti SM. Maintenance acne treatment with topical tazarotene after oral isotretinoin: overview and case reports. J Clin Aesthet Dermatol. 2024;17(11-12 Suppl 1):S14-s17.
Tanghetti EA, Zeichner JA, Gold M, Sadick N, Cook-Bolden FE, Kircik LH, et al. Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin. J Dermatolog Treat. 2023;34(1):2147391. doi:10.1080/09546634.2022.2147391 DOI: https://doi.org/10.1080/09546634.2022.2147391
Del Rosso J, Stein Gold L, Tyring S, Zeichner J, Callender V, Draelos Z, et al. Efficacy and Safety of tazarotene 0.045% lotion in Caucasian adults with moderate-to-severe acne. J Drugs Dermatol. 2022;21(10):1061-1069. doi:10.36849/jdd.6834 DOI: https://doi.org/10.36849/JDD.6834
Stein Gold L, Kircik L, Baldwin H, Callender V, Tanghetti E, Del Rosso J, et al. Tazarotene 0.045% lotion for females with acne: analysis of two adult age groups. J Drugs Dermatol. 2022;21(6):587-595. doi:10.36849/jdd.6876 DOI: https://doi.org/10.36849/JDD.6876
Issa N, Alexis A, Baldwin H, Hamzavi I, Hebert A, Kwong P, et al. Recommendations to improve outcomes in acne and acne sequelae: a focus on trifarotene and other retinoids. Dermatol Ther (Heidelb). 2025;15(3):563-577. doi:10.1007/s13555-025-01344-y DOI: https://doi.org/10.1007/s13555-025-01344-y
Tan J, Chavda R, Baldwin H, Dreno B. Management of acne vulgaris with trifarotene. J Cutan Med Surg. 2023;27(4):368-374. doi:10.1177/12034754231163542 DOI: https://doi.org/10.1177/12034754231163542
Conte S, Li MK. An overview on the management of atrophic acne scars: the role of trifarotene as an adjunct. Skin Therapy Lett. 2024;29(4):1-4.
Eichenfield L, Kwong P, Lee S, Krowchuk D, Arekapudi K, Hebert A. Advances in topical management of adolescent facial and truncal acne: a phase 3 pooled analysis of safety and efficacy of trifarotene 0.005% cream. J Drugs Dermatol. 2022;21(6):582-586. doi:10.36849/jdd.6778 DOI: https://doi.org/10.36849/JDD.6778
Conte S, Li MK. A multimodal approach to acne-induced post-inflammatory hyperpigmentation: trifarotene as a long-term intervention. Skin Therapy Lett. 2024;29(6):1-5.
Kircik L. Efficacy and safety of tazarotene lotion, 0.045% in the treatment of truncal acne vulgaris. J Drugs Dermatol. 2022;21(7):713-716. doi:10.36849/jdd.6967
Shergill M, Ali MU, Abu-Hilal M. Comparison of the efficacy of clascoterone, trifarotene, and tazarotene for the treatment of acne: a systematic literature review and meta-analysis. Dermatol Ther (Heidelb). 2024;14(5):1093-1102. doi:10.1007/s13555-024-01175-3 DOI: https://doi.org/10.1007/s13555-024-01175-3
Tan J, Knezevic S. Improving bioavailability with a novel isotretinoin formulation (isotretinoin-Lidose). Skin Therapy Lett. 2013;18(6):1-3.
Jones M, Armstrong AW, Baldwin H, Stein Gold L, Kircik LH. ARTICLE: Advances in oral isotretinoin therapy. J Drugs Dermatol. 2021;20(5):s5-s11. doi:10.36849/JDD.s072A
Xia E, Han J, Faletsky A, Baldwin H, Beleznay K, Bettoli V, et al. Isotretinoin laboratory monitoring in acne treatment: a delphi consensus study. JAMA Dermatol. 2022;158(8):942-948. doi:10.1001/jamadermatol.2022.2044 DOI: https://doi.org/10.1001/jamadermatol.2022.2044
El Arabi Y, Hali F, Chiheb S. Laser management and safety in dermatology. Cureus. 2022;14(6):e25991. doi:10.7759/cureus.25991 DOI: https://doi.org/10.7759/cureus.25991
Jih MH, Kimyai-Asadi A. Laser treatment of acne vulgaris. Semin Plast Surg. 2007;21(3):167-174. doi:10.1055/s-2007-991185 DOI: https://doi.org/10.1055/s-2007-991185
Bittar J, Hooper P, Dover JS. 1726 nm lasers for the treatment of acne vulgaris. Skin Therapy Lett. 2024;29(1):5-7.
Pulumati A, Jaalouk D, Algarin YA, Kasheri E, Issa NT, Nouri K. Targeting sebaceous glands: a review of selective photothermolysis for Acne Vulgaris treatment. Arch Dermatol Res. 2024;316(7):356. doi:10.1007/s00403-024-02979-1 DOI: https://doi.org/10.1007/s00403-024-02979-1
Wafae BGO, Barbieri JS. Innovations in acne. Dermatol Clin. 2025;43(1):11-25. doi:10.1016/j.det.2024.08.002 DOI: https://doi.org/10.1016/j.det.2024.08.002
Lipson J. Adult female acne: managing the hormones. Skin Therapy Lett. 2024;29(4):5-7.
Del Rosso JQ, Kircik LH, Stein Gold L, Thiboutot D. Androgens, androgen receptors, and the skin: from the laboratory to the clinic with emphasis on clinical and therapeutic implications. J Drugs Dermatol. 2020;19(3):30-35.
Ebede TL, Arch EL, Berson D. Hormonal treatment of acne in women. J Clin Aesthet Dermatol. 2009;2(12):16-22.
Smith CA, Gosnell E, Karatas TB, Deitelzweig C, Collins EMB, Yeung H. Hormonal therapies for acne: a comprehensive update for dermatologists. Dermatol Ther (Heidelb). 2025;15(1):45-59. doi:10.1007/s13555-024-01324-8 DOI: https://doi.org/10.1007/s13555-024-01324-8
Renz S, Chinnery F, Stuart B, Day L, Muller I, Soulsby I, et al. Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women. BMJ Open. 2021;11(8):e053876. doi:10.1136/bmjopen-2021-053876 DOI: https://doi.org/10.1136/bmjopen-2021-053876
Vargas-Mora P, Morgado-Carrasco D. Spironolactone in dermatology: uses in acne, hidradenitis suppurativa, female pattern baldness, and hirsutism. Actas Dermosifiliogr (Engl Ed). 2020;111(8):639-649. doi:10.1016/j.ad.2020.03.001 DOI: https://doi.org/10.1016/j.adengl.2020.03.015
Lin A, Chan SJ, Crapanzano JP, Kuo EJ. Severe hypokalaemia in primary aldosteronism during pregnancy. BMJ Case Rep. 2025;18(2). doi:10.1136/bcr-2024-262767 DOI: https://doi.org/10.1136/bcr-2024-262767
Pfizer. ALDACTONE® Use in Specific Populations [Webpage]. 2025; [cited 16 May 2025]. [Available from: https://www.pfizermedicalinformation.com/aldactone/population-use#:~:text=Based%20on%20mechanism%20of%20action,exposed%20to%20spironolactone%20in%20utero.
Ghaoui N, Hanna E, Abbas O, Kibbi AG, Kurban M. Update on the use of dapsone in dermatology. Int J Dermatol. 2020;59(7):787-795. doi:10.1111/ijd.14761 DOI: https://doi.org/10.1111/ijd.14761
Tanghetti E, Dhawan S, Green L, Ling M, Downie J, Germain MA, et al. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. J Drugs Dermatol. 2011;10(7):783-792.
McMullan P, Yaghi M, Truong TM, Rothe M, Murase J, Grant-Kels JM. Safety of dermatologic medications in pregnancy and lactation: an update - Part I: Pregnancy. J Am Acad Dermatol. 2024;91(4):619-648. doi:10.1016/j.jaad.2023.10.072 DOI: https://doi.org/10.1016/j.jaad.2023.10.072
Bozzo P, Chua-Gocheco A, Einarson A. Safety of skin care products during pregnancy. Can Fam Physician. 2011;57(6):665-667.
Gerhardy L, Nassar N, Litchfield M, Kennedy D, Smith A, Gillies MB, et al. Prescription retinoid and contraception use in women in Australia: a population-based study. Australas J Dermatol. 2024;65(5):428-436. doi:10.1111/ajd.14294 DOI: https://doi.org/10.1111/ajd.14294
Bertels X, Mehuys E, Boussery K, Lahousse L. The implementation of risk minimization measures to prevent teratogenic pregnancy outcomes related to oral retinoid and valproate use in Belgium. Acta Clin Belg. 2022;77(5):815-822. doi:10.1080/17843286.2021.1983708 DOI: https://doi.org/10.1080/17843286.2021.1983708
Paik J. Topical minocycline foam 4%: a review in acne vulgaris. Am J Clin Dermatol. 2020;21(3):449-456. doi:10.1007/s40257-020-00523-1 DOI: https://doi.org/10.1007/s40257-020-00523-1
Raoof TJ, Hooper D, Moore A, Zaiac M, Sullivan T, Kircik L, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: a phase 3 study. J Am Acad Dermatol. 2020;82(4):832-837. doi:10.1016/j.jaad.2019.05.078 DOI: https://doi.org/10.1016/j.jaad.2019.05.078
Kontzias C, Zaino M, Feldman SR. Tretinoin 0.1% and benzoyl peroxide 3% cream for the treatment of facial acne vulgaris. Ann Pharmacother. 2023;57(9):1088-1093. doi:10.1177/10600280221147338 DOI: https://doi.org/10.1177/10600280221147338
Avila A. What’s going on with benzoyl peroxide? : The Strategist; 2025 [Available from: https://nymag.com/strategist/article/what-is-going-on-with-benzoyl-peroxide-benzene.html.
Conte S, Lagacé F, Netchiporouk E, Sasseville D, Litvinov IV. Benzene, a known human carcinogen, detected in suncare products. J Cutan Med Surg. 2021;25(6):650-651. doi:10.1177/12034754211034507 DOI: https://doi.org/10.1177/12034754211034507
Valisure. FDA Citizen Petition #8: Benzene in Benzoyl Peroxide Products: Valisure; 2025; [cited 2025 11 May]. Available from: https://www.valisure.com/valisure-newsroom/fda-citizen-petition-8-benzene-in-benzoyl-peroxide-products.
Kucera K, Zenzola N, Hudspeth A, Dubnicka M, Hinz W, Bunick CG, et al. Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products. J Invest Dermatol. 2024. doi:10.1016/j.jid.2024.09.009 DOI: https://doi.org/10.1289/EHP13984
Taylor SC. American Academy of Dermatology statement on Benzoyl Peroxide in OTC Personal Care Products: American Academy of Dermatology Association; 2025 [Available from: https://www.aad.org/news/benzoyl-peroxide-personal-care-products.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Canadian Primary Care Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
